Home › Parkinson's Disease › NCT06013956
Personalized Real-Time DBS and PD Mechanisms
Identifying Circuit Dynamics Underlying Motor Dysfunction in Parkinson's Disease Using Real-Time Neural Control
Who can join
Ages 18 to 80 · All sexes
Full eligibility criteria
Key Inclusion Criteria: * Ability to provide informed consent. * Clinical diagnosis of idiopathic Parkinson's disease. * Determined, as per standard of care, to be a candidate for deep brain stimulation (DBS) surgery targeting the subthalamic nucleus. * Ability to tolerate delays in taking daily standard Parkinson's disease medications. Key Exclusion Criteria: * Secondary Parkinsonism, stroke, or progressive central nervous system disease other than Parkinson's disease. * Patient has a condition that, in the opinion of the investigators, would significantly increase the risk of interfering with study compliance, safety, or outcome.
About the study
A prospective cohort of patients scheduled to undergo deep brain stimulation (DBS) implantation surgery for the treatment of Parkinson's disease as per standard of care will be invited to participate in this study. This mechanistic study is aimed at better understanding the role of basal ganglia beta band (11-35 Hz) oscillations and resonance in the manifestation of Parkinson's disease (PD) motor signs using closed-loop electrical neurostimulation, levodopa medication, and computational modeling. The ultimate goal of this study is to inform the development of closed-loop neuromodulation technology that can be programmed and adjusted in real time based on patient-specific neural activity.
What is being tested
- Neurostimulation (device)
- Carbidopa 25/Levodopa 100Mg Tab (drug)
Sponsor: David Escobar · Participants: 25 · Started: Aug 29, 2023
Contact the study team
- David Escobar, PhD · Phone: 216-390-1907
- Jeffrey Negrey, MA · Phone: 216-316-6896
Official record on ClinicalTrials.gov — NCT06013956
Locations in the U.S.
| Ohio | Cleveland Clinic, Cleveland |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.